BCHE and early-onset autosomal dominant Alzheimer disease: Donepezil is the most commonly prescribed cholinesterase inhibitor for treating Alzheimer’s disease, which reversibly inactivates acetylcholinesterase, thereby inhibiting the hydrolysis of acetylcholine and increasing its concentration in the synaptic space of cholinergic neurons (Bryson and Benfield, 1997).